63 Biggest Movers From Yesterday
Gainers
InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire.
Why Ampio Pharmaceuticals Stock Is Rising Today
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage.
Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well above current levels.
Alliance Global Partners Initiates Coverage On Ampio Pharmaceuticals with Buy Rating, Announces Price Target of $4.5
Alliance Global Partners analyst James Molloy initiates coverage on Ampio Pharmaceuticals (AMEX:AMPE) with a Buy rating and announces Price Target of $4.5.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Ampio Pharmaceuticals CEO Mike Martino Issues Letter To Stockholders
Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today released the following letter to
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Ampio Pharmaceuticals Granted U.S. Patent Titled ‘Methods for treating diseases associated with respiratory viruses’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5276&f=G&l=50&d=PTXT&p=106&S1=20210928&OS=20210928&RS=20210928